Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

  title={Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.},
  author={James A. Lofgren and Sripriya Dhandapani and Jason J. Pennucci and Christina M. Abbott and Daniel T. Mytych and Arunan Kaliyaperumal and Steven J. Swanson and Michael C. Mullenix},
  journal={Journal of immunology},
  volume={178 11},
Evaluation of the immunogenicity of panitumumab, a fully human anti-epidermal growth factor receptor mAb approved for use in colorectal cancer patients, led to the development of two separate immunoassays for the detection of anti-panitumumab Abs. The first immunoassay used a bridging ELISA capable of detecting 10 ng/ml positive control anti-panitumumab Ab. The ELISA incorporated an acid dissociation step to reduce drug interference and tolerated the presence of approximately 100-fold molar… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 64 extracted citations

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility.

Biologicals : journal of the International Association of Biological Standardization • 2015
View 9 Excerpts
Highly Influenced

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…